ANDERSON P M ET AL: "G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells." BLOOD 1 DEC 1992, vol. 80, no. 11, 1 December 1992 (1992-12-01), pages 2826-2834, XP002572418 ISSN: 0006-4971 (B1)

Anomynous: "Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-Precursor Acute ALL" 11 August 2008 (2008-08-11), 11 August 2008 (2008-08-11), XP002572438 Retrieved from the Internet: URL:http://clinicaltrials.gov/archive/NCT0 0560794/2008_08_11> [retrieved on 2010-03-10] (B1)

BARGOU RALF ET AL: "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody." SCIENCE (NEW YORK, N.Y.) 15 AUG 2008, vol. 321, no. 5891, 15 August 2008 (2008-08-15), pages 974-977, XP002572417 ISSN: 1095-9203 (B1)

WO-A1-98/08875 (B1)

LÖFFLER A ET AL: "A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes." BLOOD 15 MAR 2000, vol. 95, no. 6, 15 March 2000 (2000-03-15) , pages 2098-2103, XP002572419 ISSN: 0006-4971 (B1)

PUI CHING-HON ET AL: "Acute lymphoblastic leukaemia." LANCET 22 MAR 2008, vol. 371, no. 9617, 22 March 2008 (2008-03-22), pages 1030-1043, XP002574385 ISSN: 1474-547X (B1)

WO-A1-2007/068354 (B1)

HANDGRETINGER R ET AL: "Complete remission after blinattumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acutre lymphoblastic leukemia", LEUKEMIA, vol. 25, 2011, pages 181-184, (B1)